Influence of Fampridine on Working Memory in Healthy Young Subjects

Working Memory Clinical Trial

— FamH  

Official title:

Randomized Placebo-controlled Phase II Cross-over Study on the Influence of Fampridine on Working Memory in Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04652557
• Other study ID #: 2020-02828
• Status: Completed
• Phase: Phase 2
• Start date: November 1, 2021
• Est. completion date: January 26, 2023

Study information

• Verified date: February 2023
• Source: University of Basel
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Proof of concept study on the acute effects on working memory of 10 mg fampridine SR as well as the effects after repeated administration of 10 mg twice daily (3.5 days). The hypothesis ist that fampridine improves working memory performance.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 44
• Est. completion date: January 26, 2023
• Est. primary completion date: January 26, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 30 Years

Eligibility

Inclusion Criteria:

• male or female
• generally healthy
• normotensive (BP between 90/60mmHg and 140/90mmHg)
• BMI between 19 and 29,9 kg/m2
• aged between 18 and 30 years
• fluent German-speaking
• IC as documented by signature
• at least double vaccination against Covid-19

Exclusion criteria:

• contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to 4-aminopyridine
• use of potassium channel blockers within the last 3 months
• concomitant treatment with OCT 2 inhibitors and substrates (e.g. cimetidine, propranolol)
• acute or chronic psychiatric disorder (e.g. major depression, psychoses, somatoform disorder, suicidal tendency)
• acute cerebrovascular condition
• history of seizures
• risk of lowered seizure threshold (due to e.g. sleep deprivation, withdrawal of alcohol after alcohol abuse)
• renal impairment
• history of malignant cancers
• walking problems (e.g. due to dizziness)
• bradycardia > 50/min during clinical examination
• clinically significant concomitant disease states (e.g. hepatic dysfunction, cardiovascular disease, diabetes, asthma)
• clinically significant laboratory or ECG abnormality that could be a safety issue in the study
• known or suspected non-compliance
• drug or alcohol abuse
• inability to follow the procedures of the study, e.g. due to language or psychological problems of the participant
• participation in another study with an investigational drug within the 30 days preceding and during the present study
• prior participation (less than two years ago) in a study investigating working memory (notably the n-back task)
• enrolment of the investigator, his/her family members, employees and other dependent persons
• smoking (>3 cigarettes per day)
• intake of psychoactive drugs (e.g. benzodiazepines, antidepressants, neuroleptics)
• pregnancy or breast feeding
• experiencing a syncope during basal rMT measuring
• metal in the brain, skull or elsewhere in the body (e.g., splinters, fragments, clips, etc.)
• implanted neurostimulator (e.g., DBS, epidural/subdural, VNS)
• cardiac pacemaker or intracardiac lines
• medication infusion device
• piercings, pivot teeth (retainers are no exclusion criterion)
• tattoos (head area) less than 3 months old or older than 20 years
• condition after neurosurgery
• hearing problems or tinnitus
• not able to sit still due to tremor, tics, itching
• history of repeated syncope
• head trauma diagnosed as concussion or associated with loss of consciousness
• diagnosis of epilepsy, or a convulsion or a seizure in the past of the participant or his family
• TMS in the past showing problems
• MRI in the past showing problems
• surgical procedures to spinal cord
• spinal or ventricular derivations

Related Conditions & MeSH terms

• Working Memory

Intervention

Drug:
• Fampridine SR
Fampridine SR is an inhibitor of voltage gated potassium channels and is approved in Switzerland for treatment of gait problems in patients with Multiple Sclerosis (MS).
• Placebo
no active component

Locations

Country	Name	City	State
Switzerland	University of Basel, Transfaculty Research Platform	Basel	BS

Sponsors (3)

Lead Sponsor	Collaborator
Prof. Dominique de Quervain, MD	Clinical Trial Unit, University Hospital Basel, Switzerland, University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	High-load working-memory performance after repeated administrations (3.5 days)	It will be used the letter n-back task (Heck, Fastenrath et al. 2014)) which includes a 3-back task assessing working memory. The 3-back task requires participants to respond to a letter repeat with two intervening letters (for example, S-m-b-s-g…). Performance will be quantified with the d' measure controlling for false positives. It will be used parallel versions (different sequences) for the four test days. Primary outcome will be performance after repeated intake of study medication.	test days 2 and 4 (end of treatment periods; 4 hours after last intake of fampridine SR) to assess changes between the Verum and Placebo condition
Secondary	High-load working-memory performance after acute administration	It will be used the letter n-back task (Heck, Fastenrath et al. 2014)) which includes a 3-back task assessing working memory. The 3-back task requires participants to respond to a letter repeat with two intervening letters (for example, S-m-b-s-g…). Performance will be quantified with the d' measure controlling for false positives. It will be administered parallel versions (different sequences) for the four test days. Primary outcome will be performance after repeated intake of study medication.	test days 1 and 3 (beginning of treatment periods; 4 hours after first intake of fampridine SR) to assess differences between the Verum and Placebo condition
Secondary	Reaction time after acute and repeated intake	Reaction time for correct answers in the 3-back (d') task (see outcomes 1 and 2)	test days 1 and 3 (beginning of treatment periods; 4 hours after first intake of fampridine SR) to assess differences between the Verum and Placebo condition
Secondary	Attention after acute and repeated administration	Performance in a 0-back task (d' measure controlled). It will be used parallel versions (different sequences) for the four test days.	first and last day of treatment periods (each 4 hours after intake in the morning); to assess differences between the Verum and Placebo condition
Secondary	Symbol Digit Modalities Test (SDMT; Smith 1973) after acute and repeated intake	The test consists of the presentation of a series of 9 symbols, each of them is paired with a single digit, labeled 1-9, in a key at the top of a sheet. The remainder of the page has a pseudo-randomized sequence of the symbols and the participant must respond with the digit associated with each of these as quickly as possible. The score is the number of correct answers in 90 seconds (max. 110). The administration of SDMT will be preceded by a learning sequence at both timepoints. It will be used parallel versions for all test days.	first and last day of treatment periods (each 4 hours after intake in the morning); to assess differences between the Verum and Placebo condition
Secondary	Fluid intelligence (Gf): Bochumer Matrizentest (BOMAT)	Bochumer Matrizentest (BOMAT - advanced -short; Hossiep/Turck/Hasella, 2001, 1st edition), matrix reasoning. It will be administered the BOMAT to measure fluid intelligence (Gf) consisting of 20 items (maximum 20 correct answers possible). Parallel versions will be used for the four test days. It will be used a time-limited version according to Jaeggi (Jaeggi 2010).	first and last day of treatment periods (each 4 hours after intake in the morning); to assess differences between the Verum and Placebo condition
Secondary	Working-memory: Digit Span Task	Working memory will be also assessed with the digit span task, a subtest of the "Wechsler Intelligenztest für Erwachsene" (WIE;(von Aster 2006)). Total scores for digit span forward and backward will be calculated as described in the manual of the WIE. Parallel version will be used for the four test days.	first and last day of treatment periods (each 4 hours after intake in the morning); to assess differences between the Verum and Placebo condition
Secondary	Resting motor threshold (rMT)	The resting motor threshold (rMT) will be measured by transcranial magnetic stimulation (TMS). rMT will be determined by measuring the motor evoked potential (MEP) in the abductor digiti minimi according to Rossini (2001). rMT will be defined as the lowest stimulation intensity by stimulating the primary motor cortex of the left or right hemisphere required to induce an MEP in the abductor digiti minimi of the dominant hand in at least 5 out of 10 trials.	test days 2 and 4 (last day of treatment periods; approx. 5 hours after last intake of fampridine SR) to assess differences between the Verum and Placebo condition